Life sciences platform for Merck

NextBio, provider of a platform that enables life science researchers to search, discover and share knowledge within public and proprietary data, has reached a licensing agreement with Merck & Co., Inc. NextBio offers the life sciences enterprise secure data access, knowledge discovery and collaboration tools, and enterprise integration capabilities for seamless correlation of internal research data. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment. NextBio is used by over a million researchers and has been deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Regeneron, Scripps Research Institute, Stanford University, and Takeda, among many others. http://www.nextbio.com.